Carregando...
Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer
Phase III clinical trials evaluating bevacizumab (an antibody to the angiogenic ligand, VEGF-A) in breast cancer have found improved responses in the presurgical neoadjuvant setting but no benefits in the postsurgical adjuvant setting. The objective of this study was to evaluate alternative antiangi...
Na minha lista:
| Publicado no: | Sci Rep |
|---|---|
| Principais autores: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5107907/ https://ncbi.nlm.nih.gov/pubmed/27841282 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep36694 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|